{
    "2019-10-07": [
        [
            {
                "time": "2018-03-15",
                "original_text": "52-Week Company Lows",
                "features": {
                    "keywords": [
                        "52-Week",
                        "Company",
                        "Lows"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit",
                "features": {
                    "keywords": [
                        "Thermo Fisher",
                        "Closes",
                        "API",
                        "Site",
                        "Buyout",
                        "Fortifies",
                        "Pharma",
                        "Unit"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-20",
                "original_text": "Novo Nordisk Focuses on Pipeline Development Amid Competition",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Focuses",
                        "Pipeline",
                        "Development",
                        "Amid",
                        "Competition"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-06-15",
                "original_text": "Lilly's CYRAMZAÂ® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology",
                "features": {
                    "keywords": [
                        "Lilly",
                        "CYRAMZA",
                        "Phase",
                        "3",
                        "Data",
                        "First-Line",
                        "EGFR-Mutated",
                        "Non-Small",
                        "Cell",
                        "Lung",
                        "Cancer",
                        "Published",
                        "The",
                        "Lancet",
                        "Oncology"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-05",
                "original_text": "FDA approves Pfenex's osteoporosis therapy",
                "features": {
                    "keywords": [
                        "FDA",
                        "approves",
                        "Pfenex",
                        "osteoporosis",
                        "therapy"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}